Cogent Biosciences (COGT) 10-K2024 FY Annual report

Filed: 25 Feb 25, 8:38am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: Abbisko, abbreviated, adherence, adulterated, AI, AKS, Alliance, altogether, Amgen, anecdotal, arm, Asia, asymptomatic, bioequivalence, bribe, BSC, cap, CAT, CC, cholangiocarcinoma, CI, circumvented, CMS, CODM, color, colorectal, commerce, commonly, compelling, conflict, confusion, contact, culpability, curb, dealing, denied, departure, destruction, Disaggregation, divert, dossier, DPA, DPF, drawn, Eastern, Elevar, evolving, excise, exemplified, experimental, facilitate, facilitating, faster, fire, FTC, Futibatinib, futility, gave, goal, GSK, hair, hand, hazard, HRQoL, IDMC, illustration, impermissible, impinge, Incyte, instance, intercranial, interstate, intolerant, investigatory, KDR, Latin, lawfully, legitimate, lengthened, linearly, lung, maker, Measurea, mental, misbranded, mislabeled, MMDA, monotherapy, multidisciplinary, Nanjing, nil, nonpatent, offence, offense, omission, Ono, opposition, overcome, Paediatric, pan, pancreatic, passage, patentee, Pemigatinib, Pharma, PHSA, picomolar, pivotal, pM, Pooleda, Pooledb, predetermined, preset, PRIME, proactive, prompt, PTE, questioning, questionnaire, Raft, rapporteur, Ratification, rebate, relaxation, remediation, replicate, Restoration, retroactive, RLD, Sarcoma, scrutiny, se, settle, shortly, stake, Supreme, Switzerland, taxation, TEAE, therewith, threat, timepoint, traceability, transaminase, transformed, TransThera, Tyra, uniform, unlicensed, unregistered, UPC, usable, usage, weaken, weakened, willfully, Windsor, xenograft

Removed: ACA, Affordability, Affordable, aim, assumed, attained, bank, biology, chance, composed, Congressional, continual, Dr, Education, enactment, English, erected, essentially, filer, fix, formulary, growing, imply, incorporating, interplay, IPO, irrespective, John, kind, lab, Leerink, marketability, mentioned, modify, noted, pharmacoeconomic, practical, preclinically, presidential, Pretreated, profit, punishable, Robinson, sharing, strictest, supervisory, SVB, tightening, tracked, trend, twenty, uncapped, unclear, undergone, VEGFR

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

COGT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Cogent Biosciences, Inc. (the “Company”) for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Andrew Robbins, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: February 25, 2025	By:	/s/ Andrew Robbins
		Andrew Robbins
		Chief Executive Officer (Principal Executive Officer)